Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the...